Unit:
Faculty of MedicineLibrary of the School of Health Sciences
Author:
Mavridis Theodoros
Dissertation committee:
Ιακωβίδου Νικολέττα, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Ξάνθος Θεόδωρος, Καθηγητής, Σχολή Επιστημών Υγείας και Πρόνοιας, ΠΑΔΑ
Γκιόκας Γεώργιος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Μπούτσικου Θεοδώρα, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Ηλιοδρομίτη Ζωή, Αναπληρώτρια Καθηγήτρια, Iατρική Σχολή, ΕΚΠΑ
Πανουλής Κωνσταντίνος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Μητσικώστας Δήμος-Δημήτριος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Ο ρόλος των κλινικών επιδράσεων του IRL-1620 σε πειραματικό μοντέλο τραυματισμού του νωτιαίου μυελού
Translated title:
The role of the clinical effects of IRL-1620 in an experimental model of spinal cord injury
Summary:
Background: Spinal Cord Injury (SCI) presents a major global health challenge, with rising incidence and substantial disability. While progress has been made in understanding SCI's pathophysiology and early management, there is still a lack of effective treatments to mitigate long-term consequences. This study investigates the potential of sovateltide, a selective endothelin B (ETB) receptor agonist, in improving clinical outcomes in an acute SCI rat model.
Methods: Thirty male Sprague-Dawley rats underwent sham surgery (Group A) or spinal cord injury (SCI) and treated with vehicle (Group B) or sovateltide (Group C). Clinical tests, including Basso, Beattie, and Bresnahan (BBB) scoring, inclined plane, and allodynia testing with Von Frey Hair, were performed at various time points. Statistical analyses assessed treatment effects.
Results: Sovateltide administration significantly improved motor function, reducing neurological deficits and enhancing locomotor recovery compared to vehicle-treated rats, starting from day 7 post-injury. Additionally, the allodynic threshold improved, suggesting anti-nociceptive properties. Notably, the sovateltide group demonstrated sustained recovery, and even reaching preinjury performance levels, while the vehicle group plateaued.
Conclusions: This study suggests that sovateltide may offer neuroprotective effects, enhancing neurogenesis and angiogenesis. Furthermore, it may possess anti- inflammatory and antinociceptive properties. Future clinical trials are needed to validate these findings, but sovateltide shows promise as a potential therapeutic strategy to improve functional outcomes in SCI. Sovateltide, an ETB receptor agonist, exhibits neuroprotective properties, enhancing motor recovery and ameliorating hyperalgesia in a rat SCI model. These findings could pave the way for innovative pharmacological interventions for SCI in clinical settings.
Main subject category:
Health Sciences
Keywords:
Allodynia, ETB receptor agonist, ILR-1620, Neuroprotective therapy, Spinal cord injury treatment
Number of references:
239
